A new blood test, the Destinex assay, accurately identified gastric cancer — even at its earliest stage — in a study of 809 specimens from 480 patients. These results position Destinex as a promising, noninvasive tool that could transform screening and save lives. Funded by the AGA Research Foundation’s Robert & Sally Funderburg Research Award in Gastric Cancer, this work highlights innovative approaches to fight a disease that remains the third leading cause of cancer-related deaths worldwide, largely because it is often diagnosed too late and current screening relies on invasive, costly endoscopy.
AGA-funded researcher: Ajay Goel, MD, 2020 Funderburg
This work was published in JAMA Surgery.
Read more in Medscape.